Its effectiveness is promising, with the TRIUMPH-1 Phase 3 trial revealing that participants achieved up to a 28.3% reduction in body weight over 80 weeks
Keep it out of the light to prevent degradation
The pharmaceutical industry's evolution in obesity therapeutics has progressed from single-target approaches (pure GLP-1 agonists like semaglutide) to dual agonists (GLP-1/GIP like tirzepatide), and now to triple agonists like retatrutide that attempt to orchestrate an even more comprehensive metabolic remodeling by simultaneously modulating multiple complementary pathways
Lancet 392 , 637649 (2018)
Front Endocrinol (Lausanne)
The receptor is a class B G-protein-coupled receptor that signals mainly through cyclic AMP, and it is expressed far beyond the pancreas, in the brain, gut, vasculature, heart, and kidney